Lentivi­ral vec­tor short­age looms un­less man­u­fac­tur­ing hur­dles from clin­i­cal to com­mer­cial are ad­dressed

With the an­tic­i­pa­tion that more gene ther­a­pies will en­ter the mar­ket, man­u­fac­tur­ers could strug­gle to meet de­mand if lentivi­ral vec­tor short­age risk is not tack­led …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER